Molecular predictive and prognostic markers in non-small-cell lung cancer

High Expression of Bcl-2 Protein Predicts Favorable Outcome in Non-small Cell Lung Cancer: Evidence from a Systematic Review and Meta-analysis

“…To generate useful prognostic markers for NSCLC, one way is analyzing basic clinicopathological features by basic laboratory methods (Kaya et al, 2013) and another way is characterization of proteins and genes involve in tumor initiation and progression process at molecular level (Coate et al, 2009). Base on biological pathways, NSCLC prognostic markers are divided into several categories, including oncogenes or proto-oncogenes (e.g.…”

“…EGFR) and markers of aggressive characteristics, such as angiogenesis (e.g. VEGF) (Mitsudomi et al, 2000;Mascaux et al, 2005;Bremnes et al, 2006;Rosell et al, 2007;Zheng et al, 2007;Coate et al, 2009;Pirker et al, 2012). Even though these prognostic markers are identified, their effects remain controversial in different cohorts and clinical utilities are rather limited.…”

Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer

“…Current therapeutic options are chemotherapy and drug therapy directed against specific molecular targets, mainly epidermal growth factor receptor (EGFR) missense mutations and deletions, and anaplastic lymphoma kinase (ALK) rearrangements. However, response rates are generally modest and patients are still exposed to side effects of both cytotoxic agents and targeted therapy (15). Moreover, most patients are still treated with palliative chemotherapy, due to advanced disease at diagnosis.…”

HER2 as a Therapeutic Target in Ovarian Cancer

“…Mutations in both of these oncogenes are likely representative of distinct biological subsets of disease. For example, patients whose tumors harbor EGFR mutations are typically non-smokers, often female and of Asian ethnicity, and generally have a better prognosis than non-EGFR mutant NSCLC (Coate et al, 2009). The identification of patients with ovarian tumors that express either high levels of HER2, HER2 with activating mutations, or biomarkers that indicate activated HER2 signaling, such as pHER2, could enable the patients who would derive the greatest therapeutic benefit to receive HER2-targeted therapies.…”